Basic Information
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Switzerland. The company is developing a new class of potent, specific, and versatile small protein therapies called DARPins, which have potential clinical applications across a range of disease areas, including oncology, immuno-oncology, ophthalmology, and immunology. Molecular Partners is currently advancing DARPin protein therapies targeting infectious diseases and cancer.
Molecular Partners AG
Zurich,Zurich,Switzerland
51~100 people
January 01, 2004
info@molecularpartners.com

